Publication:
Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy

Simple item page
dc.contributor.authorSharifi-Rad, Javad
dc.contributor.authorSeidel, Veronique
dc.contributor.authorIzabela, Michalak
dc.contributor.authorMonserrat-Mesquida, Margalida
dc.contributor.authorSureda Gomila, Antoni
dc.contributor.authorOrmazabal, Valeska
dc.contributor.authorZuniga, Felipe A
dc.contributor.authorMangalpady, Shivaprasad Shetty
dc.contributor.authorPezzani, Raffaele
dc.contributor.authorYdyrys, Alibek
dc.contributor.authorTussupbekova, Gulmira
dc.contributor.authorMartorell, Miquel
dc.contributor.authorCalina, Daniela
dc.contributor.authorCho, William C
dc.date.accessioned2024-10-09T06:35:33Z
dc.date.available2024-10-09T06:35:33Z
dc.date.issued2023-05-01
dc.description.abstractCancer is a leading cause of death worldwide and involves an oxidative stress mechanism. The transcription factor Nrf2 has a crucial role in cytoprotective response against oxidative stress, including cancer growth and progression and therapy resistance. For this reason, inhibitors of Nrf2 are new targets to be studied. Traditional plant-based remedies rich in phytochemicals have been used against human cancers and phenolic compounds are known for their chemopreventive properties. This comprehensive review offers an updated review of the role of phenolic compounds as anticancer agents due to their action on Nrf2 inhibition. In addition, the role of naturally-occurring bioactive anticancer agents are covered in the clinical applications of polyphenols as Nrf2 inhibitors. Video Abstract.en
dc.format.number1es_ES
dc.format.page89es_ES
dc.format.volume21es_ES
dc.identifier.citationSharifi-Rad J, Seidel V, Izabela M, Monserrat-Mequida M, Sureda A, Ormazabal V, et al. Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy. Cell Commun Signal. 2023 May 1;21(1):89.en
dc.identifier.doi10.1186/s12964-023-01109-0
dc.identifier.e-issn1478-811Xes_ES
dc.identifier.journalCell communication and signaling : CCSes_ES
dc.identifier.otherhttps://hdl.handle.net/20.500.13003/18953
dc.identifier.pubmedID37127651es_ES
dc.identifier.puiL2023012224
dc.identifier.scopus2-s2.0-85157976201
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23746
dc.identifier.wos981359100004
dc.language.isoengen
dc.publisherBioMed Central (BMC)
dc.relation.publisherversionhttps://doi.org/10.1186/s12964-023-01109-0en
dc.rights.accessRightsopen accessen
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.decsFenoles*
dc.subject.decsAntineoplásicos*
dc.subject.decsNeoplasias*
dc.subject.decsHumanos*
dc.subject.decsEstrés Oxidativo*
dc.subject.decsAntioxidantes*
dc.subject.decsFactor 2 Relacionado con NF-E2*
dc.subject.meshAntioxidants*
dc.subject.meshOxidative Stress*
dc.subject.meshPhenols*
dc.subject.meshHumans*
dc.subject.meshNF-E2-Related Factor 2*
dc.subject.meshAntineoplastic Agents*
dc.subject.meshNeoplasms*
dc.titlePhenolic compounds as Nrf2 inhibitors: potential applications in cancer therapyen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication4fe896aa-347b-437b-a45b-95f4b60d9fd3
relation.isPublisherOfPublication.latestForDiscovery4fe896aa-347b-437b-a45b-95f4b60d9fd3

Files

Collections

IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)